Microbial transformation of hydroxy metabolites of 1-oxohexyl derivatives of theobromine by Cunninghamella echinulata NRRL 1384

Letters in Applied Microbiology

Volumn 48, Issue 1, 2009, Pages 19-24

  Pekala E ^a   Kochan, M ^a   Carnell, A J ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Biotransformation; Cunninghamella echinulata; Hydroxy metabolites; Pentoxifylline; Propentofylline; S selective oxidation

Indexed keywords

BIOMOLECULES; ENANTIOMERS; GLUCOSE; METABOLITES; OXIDATION;

% REDUCTIONS; BIOTRANSFORMATION; CUNNINGHAMELLUM ECHINULATUM; ENANTIOMERIC EXCESS; HYDROXY METABOLITES; MICROBIAL TRANSFORMATION; PENTOXIFYLLINE; PROPENTOFYLLINE; S-SELECTIVE OXIDATION; SELECTIVE OXIDATION;

BIOCONVERSION;

GLUCOSE; THEOBROMINE;

BIOCONVERSION; FUNGI; GLUCOSE; METABOLITES; MICROBIOLOGY; OXIDATION;

BIOTRANSFORMATION; FUNGUS; METABOLITE; MICROBIAL ACTIVITY; REDUCTION;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; CUNNINGHAMELLA ECHINULATA; ENANTIOMER; NONHUMAN; OXIDATION; STEREOCHEMISTRY;

CUNNINGHAMELLA ECHINULATA; FUNGI;

EID: 58149289716     PISSN: 02668254     EISSN: 1472765X     Source Type: Journal    
DOI: 10.1111/j.1472-765X.2008.02478.x     Document Type: Article

References (30)

1. Abel, A.M., Carnell, A.J., Davis, J.A. Paylor, M. (2003) The synthesis of buprenorphine intermediates by regioselective microbial N- and O-demethylation reactions using Cunninghamella echinulata. Enzyme Microb Technol 33, 743 748.
2. Aretz, W., Furrer, H., Gebert, U. Hinze, H.J. (1991) Process for the enantioselective preparation of (-1)-hydroxyalkyl xanthines Hoechst) Patent DE3942872.
3. Cardus, G.J., Gareth, J., Carnell, A.J., Trauthwein, H. Riermeir, T. (2004) Microbial deracemisation of N-(1-hydroxy-1-phenylethyl)benzamide. Tetrahedron Asymmetry 15, 239 243.
4. Dorazil-Dudzik, M., Mitka, J., Schafer, M., Li, Y., Obara, I., Wordliczek, J. Przewłocka, B. (2004) The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg 98, 1566 1573.
5. Duhart, B.T., Zhang, D., Deck, J., Freeman, J.P. Cerniglia, C.E. (1999) Biotransformation of protriptyline by filamentous fungi and yeasts. Xenobiotica 29, 733 746.
6. Furrer, H., Gebert, U. Rudolphi, K. (1995) R-(-)-1-(5-hydroxyheksyl)-3- methyl-7-propylxanthine, process for its preparation and pharmaceuticals containing this compounds Hoechst), Patent US5407815.
7. Koriyama, Y., Chiba, K. Mohri, T. (2003) Propentofylline protects beta-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. Eur J Pharmacol 458, 235 241.
8. Kuroda, N., Hamachi, Y., Aoki, N., Wada, M., Tanigawa, M. Nakashima, K. (1999) Simple and rapid high-performance liquid chromatography analysis of propentofylline and its main metabolites in serum using a direct injection technique. Biomed Chromatogr 13, 340 343.
9. Lilibridge, J.A., Kalhorn, T.F. Slattery, J.T. (1996) Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 24, 1174 1179.
10. List, A.F., Maziarz, R., Stiff, P., Jansen, J., Liesveld, J., Andrews, F., Schuster, M., Wolff, S. et al. (2000) A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogenic bone marrow transplant recipients. The lisofylline marrow transplant study group. Bone Marrrow Transplant 25, 83 91.
11. Lynch, R.E. (2002) Lisofylline: anti-acute respiratory distress syndrome or just anti-inflammatory. Crit Care Med 30, 246 247.
12. Mancinelli, S., Pace, S., Marzo, A. Martelli, E.A. (1992) Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 575, 101 107.
13. Margolin, K., Atkins, M., Sparano, J., Sosman, J., Weiss, G., Lotze, M., Doroshow, J., Mier, J. et al. (1997) Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 3, 565 572.
14. Mazier, C., Jaouen, M., Sari, M.A. Buisson, D. (2004) Microbial oxidation of terfenadine and ebastine into flexofenadine and carebastine. Bioorg Med Chem Lett 14, 5423 5426.
15. Parkinson, E.E., Mukherjee, K. Geiger, J.D. (1996) [3H] adenosine transport in DDT1 MF-2 smooth muscle cells, inhibition by metabolites of propentofylline. Eur J Pharmacol 308, 97 102.
16. Pȩkala, E. Wójcik, T. (2007) Enantioselective biotransformation of pentoxifylline into lisofylline using wine yeast biocatalysis. Acta Polon Pharm Drug Res 64, 109 113.
17. Pȩkala, E., Godawska-Matysik, A. Zelaszczyk, D. (2007a) Enantioselective reduction pentoxifylline to lisofylline using whole-cell Lactobacillus kefiri biotransformation. Biotechnol J 2, 492 496.
18. Pȩkala, E., Latacz, G. Wójcik, T. (2007b) Enantioselective bioreduction of propentofylline using yeast in water and in organic solvents. Biotechnologia 2, 174 180.
19. Rao, G.P. Davis, P.J. (1997) Microbial models of mammalian metabolism. Biotransformations of HP 749 (besipiridine) using Cunninghamella elegans. Drug Metab Dispos 25, 709 715.
20. el-Sayed, K.A. (2000) Microbial models of mammalian metabolism: microbial transformation of naproxen. Pharmazie 12, 934 936.
21. Schror, R.H. (1985) Antithrombotic potential of pentoxifylline - a hemorheologically drug. Angiology 36, 387 98.
22. Semmler, J., Gebert, U., Eisenhut, U., Moeller, J., Schönharting, M.M., Allèra, A. Endres, S. (1993) Xanthine derivatives: comparison between suppression of tumor necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78, 520 525.
23. Sweitzer, S.M., Schubert, P. DeLeo, J.A. (2001) Propentofylline, a glial modulating agent, exhibits antiallodynic properties in rat model of neuropathic pain. J Pharmacol Exp Ther 297, 1210 1217.
24. Venisetty, R.K. Ciddi, V. (2003) Application of microbial botransformation for the new drug discovery using natural drugs as substrates. Curr Pharm Biotechnol 4, 153 167.
25. Wong, J.S, Keyes, S.R, Herbst, R., Coleman, C.N. Teicher, B.A. (1996) Lisofylline as a modifier of radiation theraphy. Oncol Res 8, 513 518.
26. Wyska, E., Pȩkala, E. Szymura-Oleksiak, J. (2006) Intraconversion and tissue distribution of pentoxifylline and lisofylline in mice. Chirality 18, 644 651.
27. Xie, Z.Y., Huang, H.H. Zhong, D.F. (2005) Biotransformation of pantoprazole by the fungus Cunninghamella blakesleeana. Xenobiotica 35, 467 477.
28. Yang, Z., Chen, M. Nadler, J.L (2005) Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharm 69, 1 5.
29. Zabel, P., Schade, F. Schlaak, M. (1993) Inhibition of endogenous TFN formation by pentoxifylline. Immunobiology 187, 447 463.
30. Zhong, G.F., Sun, L., Lin, L. Huang, H.H. (2003) Microbial transformation of naproxen by Cunninghamella species. Acta Pharmacol Sin 24, 442 447.